Spain (ES)

Sinonasal Tract Alveolar Rhabdomyosarcoma in Adults: A Clinicopathologic and Immunophenotypic Study of Fifty-Two Cases with Emphasis on Epithelial Immunoreactivity (2018) Thompson LDR, Jo VY, Agaimy A, Llombart-Bosch A, Morales GN, Machado I, Flucke U, et al. Journal article Variational order for forced Lagrangian systems (2018) Martín de Diego D, Sato Martín de Almagro RT Journal article, Original article Regional aerosol deposition in the human airways: The SimInhale benchmark case and a critical assessment of in silico methods (2018) Koullapis P, Kassinos S, Muela J, Perez-Segarra C, Rigola J, Lehmkuhl O, Cui Y, et al. Journal article, Original article Athena X-ray Integral Field Unit on-board Event Processor: Analysis of performance of two triggering algorithms (2018) Cobo B, Teresa Ceballos M, Peille P, Mesnager JM, Wilms J, Dauser T, Kirsch C, et al. Conference contribution QOL After APBI (Multicatheter Brachytherapy) Versus WBI: 5-Year Results, Phase 3 GEC-ESTRO Trial (2018) Schaefer R, Strnad V, Polgar C, Uter W, Hildebrandt G, Ott OJ, Kauer-Dorner D, et al. Conference contribution ESTRO-ACROP guideline: Interstitial multi-catheter breast brachytherapy as Accelerated Partial Breast Irradiation alone or as boost - GEC-ESTRO Breast Cancer Working Group practical recommendations (2018) Strnad V, Major T, Polgar C, Lotter M, Guinot JL, Gutierrez-Miguelez C, Galalae R, et al. Journal article Salvage Mastectomy Versus Second Conservative Treatment for Second Ipsilateral Breast Tumor Event: A Propensity-Score Matched Cohort Analysis (2018) Levi JMH, Van Limbergen E, Gal J, Schiappa R, Polgar C, Kauer-Dorner D, Pasquier D, et al. Conference contribution WONOEP APPRAISAL: The many facets of epilepsy networks (2018) Scott RC, De La Prida LM, Mahoney JM, Kobow K, Sankar R, De Curtis M Journal article Pitfalls in the measurement of muscle mass: a need for a reference standard (2018) Buckinx F, Landi F, Cesari M, Fielding RA, Visser M, Engelke K, Maggi S, et al. Journal article Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial (2018) Hurvitz SA, Martin M, Symmans WF, Jung KH, Huang CS, Thompson AM, Harbeck N, et al. Journal article